Effects of rosiglitazone/metformin fixed-dose combination therapy and metformin monotherapy on serum vaspin, adiponectin and IL-6 levels in drug-naïve patients with type 2 diabetes

Experimental and Clinical Endocrinology and Diabetes

Volumn 119, Issue 2, 2011, Pages 63-68

  Kadoglou, N P E ^a,b   Kapelouzou, A ^b   Tsanikidis, H ^c   Vitta, I ^a   Liapis, C D ^d   Sailer, N ^a  

^a Aristotle University Medical School   (Greece)

^b BIOMEDICAL RESEARCH FOUNDATION   (Greece)

^c Katerini General Hospital   (Greece)

^d UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

Author keywords

adiponectin; drug na ve; IL 6; metformin; rosiglitazone; type 2 diabetes; vaspin

Indexed keywords

ADIPOCYTOKINE; ADIPONECTIN; GLUCOSE; HEMOGLOBIN A1C; INTERLEUKIN 6; METFORMIN; METFORMIN PLUS ROSIGLITAZONE; PROTEIN VASPIN; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; BLOOD PRESSURE; BODY FAT; BODY MASS; DRUG EFFECT; FEMALE; GLUCOSE BLOOD LEVEL; HUMAN; INSULIN RESISTANCE; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RANDOMIZED CONTROLLED TRIAL;

ADIPONECTIN; AGED; BLOOD GLUCOSE; DIABETES MELLITUS, TYPE 2; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG COMBINATIONS; FEMALE; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN RESISTANCE; INTERLEUKIN-6; LIPIDS; MALE; METFORMIN; MIDDLE AGED; NEOADJUVANT THERAPY; SERPINS; THIAZOLIDINEDIONES;

EID: 79951672869     PISSN: 09477349     EISSN: 14393646     Source Type: Journal    
DOI: 10.1055/s-0030-1265174     Document Type: Article

References (40)

1. Andreadis EA, Katsanou PM, Georgiopoulos DX, et al. The effect of metformin on the incidence of type 2 diabetes mellitus and cardiovascular disease risk factors in overweight and obese subjects - The Carmos Study. Exp Clin Endocrinol Diabetes 2009 117 175-180
2. Buse JB, Ginsberg HN, Bakris GL, et al. American Heart Association; American Diabetes Association: Primary prevention of cardiovascular diseases in people with diabetes mellitus: a scientific statement from the American Heart Association and the Am (Pubitemid 46052519)
3. Ceriello A. Thiazolidinediones as anti-inflammatory and anti-atherogenic agents. Diabetes Metab Res Rev 2008 24 14-26 (Pubitemid 351175996)
4. Cusi K, DeFronzo RA. Metformin: a review of its metabolic effects. Diabetes Rev 1998 6 89-131 (Pubitemid 28554676)
5. Derosa G, Tinelli C, Maffioli P. Effects of pioglitazone and rosiglitazone combined with metformin on body weight in people with diabetes. Diabetes Obes Metab 2009 11 1091-1099
6. Diamond GA, Bax L, Kaul S. Uncertain effects of rosiglitazone on the risk for myocardial infarction and cardiovascular death. Ann Intern Med 2007 147 578-581 (Pubitemid 351664507)
7. Eder K, Baffy N, Falus A, et al. The major inflammatory mediator interleukin-6 and obesity. Inflamm Res 2009 58 727-736
8. Fruhbeck G. Overview of adipose tissue and its role in obesity and metabolic disorders. Methods Mol Biol 2008 456 1-22
9. Giles TD, Sander GE. Effects of thiazolidinediones on blood pressure. Curr Hypertens Rep 2007 9 332-337 (Pubitemid 47377033)
10. Gulcelik NE, Karakaya J, Gedik A, et al. Serum vaspin levels in type 2 diabetic women in relation to microvascular complications. Eur J Endocrinol 2009 160 65-70
11. Hamann A, Garcia-Puig J, Paul G, et al. Comparison of fixed-dose rosiglitazone/metformin combination therapy with sulphonylurea plus metformin in overweight individuals with type 2 diabetes inadequately controlled on metformin alone. Exp Clin Endocrinol Diabetes 2008 116 6-13 (Pubitemid 351270902)
12. Han SH, Sakuma I, Shin EK, et al. Antiatherosclerotic and anti-insulin resistance effects of adiponectin: basic and clinical studies. Prog Cardiovasc Dis 2009 52 126-140
13. Hemmingsen B, Lund SS, Wetterslev J, et al. Oral hypoglycaemic agents, insulin resistance and cardiovascular disease in patients with type 2 diabetes. Eur J Endocrinol. 2009 161 1-9
14. Hida K, Wada J, Eguchi J, et al. Visceral adipose tissue-derived serine protease inhibitor: a unique insulin-sensitizing adipocytokine in obesity. Proc Natl Acad Sci USA 2005 102 10610-10615 (Pubitemid 41061602)
15. Home PD, Pocock SJ, Beck-Nielsen H, et al. RECORD Study Team: Rosiglitazone evaluated for cardiovascular outcomes in oral agent combination therapy for type 2 diabetes (RECORD): a multicentre, randomised, open-label trial. Lancet 2009 373 2125-2135
16. Hsiao FY, Huang WF, Wen YW, et al. Thiazolidinediones and cardiovascular events in patients with type 2 diabetes mellitus: a retrospective cohort study of over 473,000 patients using the National Health Insurance database in Taiwan. Drug Saf 2009 32 675-690
17. Ibáñez L, López-Bermejo A, Díaz M, et al. Low-dose pioglitazone and low-dose flutamide added to metformin and oestro-progestagens for hyperinsulinaemic women with androgen excess: add-on benefits disclosed by a randomized double-placebo study over 24 months. Clin Endocrinol (Oxf) 2009 71 351-357
18. Jakubowska J, Bohdanowicz-Pawlak A, Milewicz A, et al. Plasma cytokines in obese women with polycystic ovary syndrome, before and after metformin treatment. Gynecol Endocrinol 2008 24 378-384 (Pubitemid 352032225)
19. Kadoglou NP, Gerasimidis T, Golemati S, et al. The relationship between serum levels of vascular calcification inhibitors and carotid plaque vulnerability. J Vasc Surg 2008 47 55-62
20. Kadoglou NP, Iliadis F, Angelopoulou N, et al. Beneficial effects of rosiglitazone on novel cardiovascular risk factors in patients with Type 2 diabetes mellitus. Diabet Med 2008 25 333-340 (Pubitemid 351322712)
21. Kadoglou NP, Tsanikidis H, Kapelouzou A, et al. Effects of rosiglitazone and metformin treatment on apelin, visfatin, and ghrelin levels in patients with type 2 diabetes mellitus. Metabolism 2010 59 373-379
22. Kim HJ, Kang ES, Kim DJ, et al. Effects of rosiglitazone and metformin on inflammatory markers and adipokines: decrease in interleukin-18 is an independent factor for the improvement of homeostasis model assessment-beta in type 2 diabetes mellitus. Clin Endocrinol (Oxf) 2007 66 282-289 (Pubitemid 46096150)
23. Kim HJ, Kim SK, Shim WS, et al. Rosiglitazone improves insulin sensitivity with increased serum leptin levels in patients with type 2 diabetes mellitus. Diabetes Res Clin Pract 2008 81 42-49
24. Klöting N, Berndt J, Kralisch S, et al. Vaspin gene expression in human adipose tissue: association with obesity and type 2 diabetes. Biochem Biophys Res Commun 2006 339 430-436 (Pubitemid 41697566)
25. Matthaei S, Bierwirth R, Fritsche A, et al. Medical antihyperglycaemic treatment of type 2 diabetes mellitus. Update of the evidence-based guideline of the German Diabetes Association. Exp Clin Endocrinol Diabetes 2009 117 522-557
26. Molavi B, Rassouli N, Bagwe S, et al. A review of thiazolidinediones and metformin in the treatment of type 2 diabetes with focus on cardiovascular complications. Vasc Health Risk Manag 2007 3 967-973
27. Monami M, Marchionni N, Mannucci E. Winners and losers at the rosiglitazone gamble A meta-analytical approach at the definition of the cardiovascular risk profile of rosiglitazone. Diabetes Res Clin Pract 2008 82 48-57
28. Nissen SE, Wolski K. Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N Engl J Med 2007 356 1-15
29. Pfützner A, Marx N, Walcher D, et al. Impact of rosiglitazone on visfatin and adiponectin plasma concentrations in patients with type 2 diabetes and coronary artery disease. Clin Lab 2008 54 237-241
30. Redinger RN. Fat storage and the biology of energy expenditure. Transl Res 2009 154 52-60
31. Ríos-Vázquez R, Marzoa-Rivas R, Gil-Ortega I, et al. Peroxisome proliferator-activated receptor-gamma agonists for management and prevention of vascular disease in patients with and without diabetes mellitus. Am J Cardiovasc Drugs 2006 6 231-242 (Pubitemid 44285132)
32. Rizos CV, Liberopoulos EN, Mikhailidis DP, et al. Pleiotropic effects of thiazolidinediones. Expert Opin Pharmacother 2008 9 1087-1108 (Pubitemid 351721748)
33. Sam S, Haffner S, Davidson MH, et al. Relation of abdominal fat depots to systemic markers of inflammation in type 2 diabetes. Diabetes Care 2009 32 932-937
34. Schernthaner G. Pleiotropic effects of thiazolidinediones on traditional and non-traditional atherosclerotic risk factors. Int J Clin Pract 2009 63 912-929
35. Seeger J, Ziegelmeier M, Bachmann A, et al. Serum levels of the adipokine vaspin in relation to metabolic and renal parameters. J Clin Endocrinol Metab 2008 93 247-251
36. Selvin E, Bolen S, Yeh HC, et al. Cardiovascular outcomes in trials of oral diabetes medications: a systematic review. Arch Intern Med 2008 168 2070-2080
37. Tan BK, Heutling D, Chen J, et al. Metformin decreases the adipokine vaspin in overweight women with polycystic ovary syndrome concomitant with improvement in insulin sensitivity and a decrease in insulin resistance. Diabetes 2008 57 1501-1507
38. von Eynatten M, Liu D, Hock C, et al. Urinary adiponectin excretion: a novel marker for vascular damage in type 2. Diabetes 2009 58 2093-2099
39. Yang T, Soodvilai S. Renal and vascular mechanisms of thiazolidinedione-induced fluid retention. PPAR Res 2008 2008 963414
40. Youn BS, Klöting N, Kratzsch J, et al. Serum vaspin concentrations in human obesity and type 2 diabetes. Diabetes 2008 57 372-327